The most common adverse effect was shingles, which occurred in 5% of patients in the low-dose group, to 10% in the high-dose group, and to 2% in the placebo group. Overall adverse effect rates were comparable in all groups.
Anifrolumab
Emapalumab
Evolocumab
Olaratumab
Avelumab
Ustekinumab
Evinacumab
Alirocumab